EMAS Position Statements and Clincial Guides
Menopause symptom management in women with dyslipidemias: An EMAS clinical guide
Worldwide, dyslipidemias are one of the leading causes of cardiovascular disease, mainly coronary heart disease [1]. Dyslipidemias are also associated with an increased risk of ischemic stroke [2]. Dyslipidemias embrace a wide constellation of lipid and lipoprotein abnormalities. Lipoproteins bind lipids and are involved in their transport. Lipid abnormalities include high serum concentrations of low-density lipoprotein (LDL) cholesterol (LDL-C) and/or triglycerides and/or low concentrations of high-density lipoprotein (HDL) cholesterol (HDL-C).Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement
The European Menopause and Andropause Society (EMAS) aims to provide holistic consensus advice on the clinical management of menopausal women through its position statements and clinical guides [1]. EMAS’s healthcare model for healthy menopause covers physical, psychological and social functioning, and incorporates disability and disease [2]. This position statement sets out a model of care for the management of depressive symptoms and depressive episodes in peri- and postmenopausal women, integrating services provided by healthcare and allied professionals.Menopause and diabetes: EMAS clinical guide
Diabetes mellitus (DM) is a public health problem, especially in developed countries. It affects about 9.1% of the adult population in Europe and 13.3% in the United States of America [1]. The greater prevalence of DM in developed countries is broadly associated with ageing of the population [2]. Between 2015 and 2030, the world population aged over 60 years is projected to increase by 56%, from 901 million to 1.4 billion; by 2050 it is expected to reach nearly 2.1 billion [3]. These data suggest that the number of postmenopausal women with DM will grow substantially.
